Compounds > 2',3'-dideoxycytidinene
Page last updated: 2024-08-24

2',3'-dideoxycytidinene and Acquired Immune Deficiency Syndrome

2',3'-dideoxycytidinene has been researched along with Acquired Immune Deficiency Syndrome in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19905 (83.33)18.7374
1990's1 (16.67)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Töglhofer, W1
Darby, G; Larder, BA; Richman, DD1
Hill, DL; Hoover, EA; Mullins, JI; Perigo, NA; Strobel, JD; Zeidner, NS1
Fukushima, S; Kawaguchi, T; Mishima, M; Nakano, M; Ohmura, M1
Broder, S; Lawley, TJ; McNeely, MC; Yarchoan, R1
Broder, S; Dalakas, M; Dubinsky, RM; Yarchoan, R1

Other Studies

6 other study(ies) available for 2',3'-dideoxycytidinene and Acquired Immune Deficiency Syndrome

ArticleYear
[New, in Austria registered specialty drugs. Hivid (2',3'-dideoxycytidine; ddC)].
    Wiener klinische Wochenschrift, 1992, Volume: 104, Issue:12

    Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Animals; Antiviral Agents; Austria; CD4-Positive T-Lymphocytes; Humans; Leukocyte Count; Zalcitabine; Zidovudine

1992
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
    Science (New York, N.Y.), 1989, Mar-31, Volume: 243, Issue:4899

    Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Dideoxynucleosides; Drug Resistance; Foscarnet; HeLa Cells; HIV; HIV Core Protein p24; Humans; Microbial Sensitivity Tests; Phosphonoacetic Acid; Retroviridae Proteins; Reverse Transcriptase Inhibitors; Viral Plaque Assay; Virus Replication; Zalcitabine; Zidovudine

1989
Treatment of FeLV-induced immunodeficiency syndrome (FeLV-FAIDS) with controlled release capsular implantation of 2',3'-dideoxycytidine.
    Antiviral research, 1989, Volume: 11, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Animals; Antibodies, Monoclonal; Capsules; Cats; Dideoxynucleosides; Disease Models, Animal; Drug Implants; Drug Therapy, Combination; Gene Products, gag; Immunologic Deficiency Syndromes; Infusions, Intravenous; Injections, Subcutaneous; Interferon Type I; Leukemia Virus, Feline; Retroviridae Proteins; Tetrahydrouridine; Tumor Necrosis Factor-alpha; Virus Replication; Zalcitabine

1989
Enzymatic and chemical stability of 2',3'-dideoxy-2',3'-didehydropyrimidine nucleosides: potential anti-acquired immunodeficiency syndrome agents.
    Chemical & pharmaceutical bulletin, 1989, Volume: 37, Issue:7

    Topics: Acquired Immunodeficiency Syndrome; Animals; Antiviral Agents; Chemical Phenomena; Chemistry; Cytarabine; Dideoxynucleosides; Drug Stability; Humans; Mice; Stavudine; Zalcitabine

1989
Dermatologic complications associated with administration of 2',3'-dideoxycytidine in patients with human immunodeficiency virus infection.
    Journal of the American Academy of Dermatology, 1989, Volume: 21, Issue:6

    Topics: Acquired Immunodeficiency Syndrome; Adult; Drug Administration Schedule; Drug Eruptions; Drug Evaluation; HIV Antigens; Humans; Male; Middle Aged; Mouth Diseases; T-Lymphocytes, Helper-Inducer; Ulcer; Zalcitabine

1989
Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2',3'-dideoxycytidine (ddC).
    Muscle & nerve, 1989, Volume: 12, Issue:10

    Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Complex; Axons; Dose-Response Relationship, Drug; Electromyography; Humans; Pain; Peripheral Nervous System Diseases; Zalcitabine

1989